跳至主要内容
临床试验/NCT01637714
NCT01637714Unknown不适用

The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome: Double-blind, Randomized, Placebo-controlled Trial

Seoul National University Hospital1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2012年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
70
试验地点
1
主要终点
change of Irritable bowel syndrome symptom severity score (IBS-SSS)

研究概览

简要总结

The investigators will evaluate the efficacy of multi-strain probiotics in adults with diarrhea predominant irritable bowel syndrome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
19 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • willing to consent/undergo necessary procedures
  • between the age of 19 and 75 years
  • diarrhea predominant irritable bowel syndrome (satisfied with Rome II criteria)

排除标准

  • uncontrolled hypertension (Blood pressure > 180/110 mmHg)
  • uncontrolled diabetes mellitus (FBS > 200 mg/dL)
  • malignancy, cerebrovascular disease, cardiovascular disease
  • history of abdominal surgery except appendectomy and hernia repair
  • inflammatory bowel disease
  • clinically or laboratory-confirmed gastroenteritis
  • the use of motility drug or dietary fiber supplement in 2 weeks
  • serum Cr > 2 x Upper normal limit
  • AST or ALT > 2 x Upper normal limit
  • Pregnancy, Lactating woman

研究组 & 干预措施

Multi-strain probiotics

Experimental

干预措施: Multi-strain probiotics (Drug)

Placebo powder

Placebo Comparator

干预措施: Placebo powder (Drug)

结局指标

主要结局

change of Irritable bowel syndrome symptom severity score (IBS-SSS)

时间窗: after 8 weeks

Severity and frequency of abdominal pain / abdominal bloating / bowel habitus / interfere degree of daily life

次要结局

  • Stool frequency and form(after 4 weeks and 8 weeks)
  • Improvement of overall symptom in patient with irritable bowel syndrome(after 4 weeks and 8 weeks)
  • Symptom control of irritable bowel syndrome(after 4 weeks and 8 weeks)
  • Assessment for patient satisfaction after administration completion(after 4 weeks and 8 weeks)
  • Assessment for quality of life related with irritable bowel syndrome(after 4 weeks and 8 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验